circROBO1 promotes prostate cancer growth and enzalutamide resistance via accelerating glycolysis

Zhou, Zhigang; Qin, Jing; Song, Cailu; Wu, Tao; Quan, Qiang; Zhang, Yan; Zou, Yani; Liu, Lingrui; Tang, Hailin; Zhao, Jianfu

doi:10.7150/jca.86940



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2023; 14(13):2574-2584. doi:10.7150/jca.86940 This issue Cite

Research Paper

circROBO1 promotes prostate cancer growth and enzalutamide resistance via accelerating glycolysis

Zhigang Zhou^1,2#, Jing Qin^2#, Cailu Song³, Tao Wu², Qiang Quan¹, Yan Zhang¹, Yani Zou^1,4, Lingrui Liu³, Hailin Tang^3✉, Jianfu Zhao^1✉

1. Research Center of Cancer Diagnosis and Therapy, Department of Oncology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
2. Changde Hospital, Xiangya School of Medicine, Central South University, Changde, 415003, China.
3. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
4. The First People's Hospital of Fuyang City, Fuyang, 236012, China.
# These authors contributed equally to this work.

Citation:

Zhou Z, Qin J, Song C, Wu T, Quan Q, Zhang Y, Zou Y, Liu L, Tang H, Zhao J. circROBO1 promotes prostate cancer growth and enzalutamide resistance via accelerating glycolysis. J Cancer 2023; 14(13):2574-2584. doi:10.7150/jca.86940. https://www.jcancer.org/v14p2574.htm

Other styles

Abstract

Background and aim: As non-coding RNAs, circular RNAs (circRNAs) contribute to the progression of malignancies by regulating various biological processes. In prostate cancer, however, there is still a lack of understanding regarding the potential molecular pathways and roles of circRNAs.

Methods: Loss-off function experiments were performed to investigate the potential biological function of circRNA in the progression of prostate cancer. Western blot, qRT-PCR, and IHC assay were used to examine the expression level of different genes or circRNAs. Further molecular biology experiments were conducted to uncover the molecular mechanism underlying circRNA in prostate cancer using dual luciferase reporter and RNA immunoprecipitation (RIP) assays.

Results: A novel circRNA (hsa_circ_0124696, named circROBO1) was identified as a significantly upregulated circRNA in both prostate cancer cells and tissues. Suppression of circROBO1 significantly attenuated the proliferation of prostate cancer cells. In addition, we found that the knockdown of circROBO1 remarkably increased the sensitivity of prostate cancer to enzalutamide treatment. A deceleration in glycolysis rate was observed after inhibition of circROBO1, which could suppress prostate cancer growth and overcome resistance to enzalutamide. Our results revealed that circROBO1 promotes prostate cancer growth and enzalutamide resistance via accelerating glycolysis.

Conclusion: Our study identified the biological role of the circROBO1-miR-556-5p-PGK1 axis in the growth and enzalutamide resistance of prostate cancer, which is the potential therapeutic target of prostate cancer.

Keywords: circROBO1, circular RNAs, PGK1, enzalutamide resistance, prostate cancer

Citation styles

APA

Zhou, Z., Qin, J., Song, C., Wu, T., Quan, Q., Zhang, Y., Zou, Y., Liu, L., Tang, H., Zhao, J. (2023). circROBO1 promotes prostate cancer growth and enzalutamide resistance via accelerating glycolysis. Journal of Cancer, 14(13), 2574-2584. https://doi.org/10.7150/jca.86940.

ACS

Zhou, Z.; Qin, J.; Song, C.; Wu, T.; Quan, Q.; Zhang, Y.; Zou, Y.; Liu, L.; Tang, H.; Zhao, J. circROBO1 promotes prostate cancer growth and enzalutamide resistance via accelerating glycolysis. J. Cancer 2023, 14 (13), 2574-2584. DOI: 10.7150/jca.86940.

NLM

CSE

Zhou Z, Qin J, Song C, Wu T, Quan Q, Zhang Y, Zou Y, Liu L, Tang H, Zhao J. 2023. circROBO1 promotes prostate cancer growth and enzalutamide resistance via accelerating glycolysis. J Cancer. 14(13):2574-2584.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.